Carisma Therapeutics Inc. (CARM)
0.23
0.01 (6.88%)
At close: Apr 25, 2025, 3:58 PM
0.21
-4.83%
After-hours: Apr 25, 2025, 05:14 PM EDT
6.88% (1D)
| Bid | 0.2 |
| Market Cap | 9.44M |
| Revenue (ttm) | 19.63M |
| Net Income (ttm) | -60.48M |
| EPS (ttm) | -1.46 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -0.35 |
| Analyst | Hold |
| Ask | 0.23 |
| Volume | 72,360 |
| Avg. Volume (20D) | 303,127 |
| Open | 0.22 |
| Previous Close | 0.22 |
| Day's Range | 0.21 - 0.23 |
| 52-Week Range | 0.16 - 1.90 |
| Beta | 2.79 |
About CARM
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collabor...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 6, 2014
Employees 46
Stock Exchange NASDAQ
Ticker Symbol CARM
Website https://carismatx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CARM stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 342.67% from the latest price.
Stock ForecastsNext Earnings Release
Carisma Therapeutics Inc. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-25.65%
Carisma Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
4 months ago
-12.82%
Carisma Therapeutics shares are trading lower after Baird downgraded the stock from Outperform to Neutral and cut its price target from $10 to $1.
